ML22334A046: Difference between revisions
Jump to navigation
Jump to search
StriderTol (talk | contribs) (StriderTol Bot insert) |
StriderTol (talk | contribs) (StriderTol Bot change) |
||
| Line 24: | Line 24: | ||
==Purpose:== | ==Purpose:== | ||
Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest. | Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest. | ||
Scheduled: | |||
Scheduled: December 6, 2022 10:00 am | |||
Duration: Approx. 2 hours | |||
Location: Commissioners Conference Room, 1st fl OWFN | |||
==Participants:== | ==Participants:== | ||
Presentation ACMUI Panel | Presentation | ||
ACMUI Panel 60 mins.* | |||
Darlene Metter, M.D., ACMUI Chair Topic: | Darlene Metter, M.D., ACMUI Chair Topic: | ||
* Overview of ACMUI activities Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic: | * Overview of ACMUI activities | ||
* ACMUIs Review of Yttrium-90 Medical Events Hossein Jadvar, M.D., Ph.D., ACMUI Nuclear Medicine Physician Topics: | |||
Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic: | |||
* ACMUIs Review of Yttrium-90 Medical Events | |||
Hossein Jadvar, M.D., Ph.D., ACMUI Nuclear Medicine Physician Topics: | |||
* Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena | * Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena | ||
* Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes Megan Shober, ACMUI Agreement States Representative Topic: | * Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes | ||
Megan Shober, ACMUI Agreement States Representative Topic: | |||
* ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators | * ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators | ||
Commissioners Q & A | Commissioners Q & A 50 mins. | ||
Discussion - Wrap-up | |||
*For presentation only and does not include time for Commission Q & As}} | Discussion-Wrap-up 5mins. | ||
* For presentation only and does not include time for Commission Q & As}} | |||
Revision as of 16:17, 15 November 2024
| ML22334A046 | |
| Person / Time | |
|---|---|
| Issue date: | 12/06/2022 |
| From: | NRC/OCM |
| To: | |
| Shared Package | |
| ML22293A439 | List: |
| References | |
| M221206 | |
| Download: ML22334A046 (2) | |
Text
AGENDA
Title:
MEETING WITH THE ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES (Public Meeting)
Purpose:
Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest.
Scheduled: December 6, 2022 10:00 am
Duration: Approx. 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br />
Location: Commissioners Conference Room, 1st fl OWFN
Participants:
Presentation
ACMUI Panel 60 mins.*
Darlene Metter, M.D., ACMUI Chair Topic:
- Overview of ACMUI activities
Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic:
- ACMUIs Review of Yttrium-90 Medical Events
Hossein Jadvar, M.D., Ph.D., ACMUI Nuclear Medicine Physician Topics:
- Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena
- Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes
Megan Shober, ACMUI Agreement States Representative Topic:
- ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators
Commissioners Q & A 50 mins.
Discussion-Wrap-up 5mins.
- For presentation only and does not include time for Commission Q & As